Announcement of the company's individual
financial report for Q2 22 has been approved by
the board of directors.
Date of events
2022/08/04
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/08/04
2.Date of the audit committee approved:2022/08/04
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2022/01/01~2022/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):213,058
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):49,083
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):3,435
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):9,510
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):7,459
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):7,459
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):0.31
11.Total assets end of the period (thousand NTD):580,837
12.Total liabilities end of the period
(thousand NTD):290,765
13.Equity attributable to owners of parent end of the
period (thousand NTD):290,072
14.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
EPS Bio Technology Corporation published this content on 04 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2022 08:36:04 UTC.
EPS Bio Technology Corp. is a Taiwan-based company principally engaged in the manufacture and sales of medical test strips and equipment. The Company's main products include blood glucose testers, blood glucose test strips and electric breast pumps. The Company distributes its products mainly to overseas markets, such as Europe, North America and the rest areas of Asia.